A phase II study of DaunoXome® in advanced urothelial transitional cell carcinoma

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1131-1132

  Fossa S D ^a   Aass, N ^a   Paro G ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Swedish Orphan AB   (Sweden)

Author keywords

DaunoXome ; Hypotensive reaction; Urothelial TCC

Indexed keywords

DAUNORUBICIN; HYDROCORTISONE; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENCAPSULATION; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

EID: 0032101833     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10156-3     Document Type: Article

References (6)

1. Scher H.I., Norton L. Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol. 8:1992;316-341.
2. Forssen E.A., Ross M.E. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposomal Res. 4:1994;481-512.
3. Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:1992;891-896.
4. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14, 2353-2364.
5. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993, 341, 1242-1243.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995, 13, 1777-1785.